Anthelmintic effect of levamisole, ivermectin, albendazole and fenbendazole on larval Toxocara canis infection in mice
- PMID: 6546805
Anthelmintic effect of levamisole, ivermectin, albendazole and fenbendazole on larval Toxocara canis infection in mice
Abstract
The anthelmintic effects of levamisole (100-50 mg kg-1 live bodyweight), ivermectin (2 mg kg-1 bodyweight), albendazole and fenbendazole (both 100 mg kg-1 bodyweight), were tested against second stage Toxocara canis larvae in mice. Anthelmintic treatment on days 2 to 7 after infection inclusive resulted in significant (P less than 0.05) retention of larvae in the liver, and fewer larvae migrated subsequently to the brain and the musculature of treated mice compared to untreated controls. Most of the larvae retained in the liver subsequently died there and were not recoverable by day 35 after infection, causing significant (P less than 0.05) reduction in the total larval recoveries compared to the controls. The oral route of drug administration caused higher larval retention in the liver than the subcutaneous route. All infected levamisole treated mice survived for four months, whereas half the similarly infected but untreated mice died within the same period. Treatment on days 8 to 13 inclusive after infection had no effect on second stage T canis larvae suggesting that once the larvae have reached the brain and musculature they are not susceptible to anthelmintic agents.
Similar articles
-
Anthelmintic effect of levamisole hydrochloride or ivermectin on tissue toxocariasis of mice.Am J Vet Res. 1987 Feb;48(2):281-3. Am J Vet Res. 1987. PMID: 3826867
-
Evaluation of follow-up of therapy with fenbendazole incorporated into stabilized liposomes and immunomodulator glucan in mice infected with Toxocara canis larvae.Acta Trop. 2007 Nov-Dec;104(2-3):122-32. doi: 10.1016/j.actatropica.2007.08.006. Epub 2007 Aug 26. Acta Trop. 2007. PMID: 17915186
-
In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans.Eur J Pharm Biopharm. 2010 Aug;75(3):451-4. doi: 10.1016/j.ejpb.2010.03.017. Epub 2010 Mar 27. Eur J Pharm Biopharm. 2010. PMID: 20347973
-
An experimental approach to the study of intraocular Toxocara canis.Trans Am Ophthalmol Soc. 1979;77:542-602. Trans Am Ophthalmol Soc. 1979. PMID: 120993 Free PMC article. Review.
-
Toward anthelmintic drug candidates for toxocariasis: Challenges and recent developments.Eur J Med Chem. 2023 May 5;251:115268. doi: 10.1016/j.ejmech.2023.115268. Epub 2023 Mar 8. Eur J Med Chem. 2023. PMID: 36921525 Review.
Cited by
-
Repertoire of P-glycoprotein drug transporters in the zoonotic nematode Toxocara canis.Sci Rep. 2023 Mar 27;13(1):4971. doi: 10.1038/s41598-023-31556-1. Sci Rep. 2023. PMID: 36973306 Free PMC article.
-
Assessment of the efficacy of thymol against Toxocara vitulorum in experimentally infected rats.J Parasit Dis. 2022 Jun;46(2):454-465. doi: 10.1007/s12639-022-01465-7. Epub 2022 Jan 30. J Parasit Dis. 2022. PMID: 35692468 Free PMC article.
-
Therapy and Prevention for Human Toxocariasis.Microorganisms. 2022 Jan 22;10(2):241. doi: 10.3390/microorganisms10020241. Microorganisms. 2022. PMID: 35208697 Free PMC article.
-
EFFICACY OF NITAZOXANIDE AGAINST Toxocara canis: LARVAL RECOVERY AND HUMORAL IMMUNE RESPONSE IN EXPERIMENTALLY INFECTED MICE.Rev Inst Med Trop Sao Paulo. 2015 Jul-Aug;57(4):337-41. doi: 10.1590/S0036-46652015000400011. Rev Inst Med Trop Sao Paulo. 2015. PMID: 26422159 Free PMC article.